Blow For Prestige As Trastuzumab Biosimilar Rejected By EMA

Tuznue And Hervelous Rivals To Herceptin Receive Negative Opinions From CHMP

Prestige Biopharma has received a setback in its attempts to win a European approval for its HD201 trastuzumab biosimilar rival to Herceptin, after the EMA’s CHMP issued a negative opinion on its parallel marketing authorization applications under the Tuznue and Hervelous labels. Prestige has 15 days in which it can ask for a re-examination of the refusals.

EU flag thumbs down
The CHMP has refused to endorse Prestige Biopharma’s trastuzumab • Source: Shutterstock

Prestige Biopharma has been frustrated in its efforts to win a European approval for its HD201 biosimilar rival to Herceptin (trastuzumab), after the European Medicines Agency’s Committee for Medicinal Products for Human Use issued negative opinions recommending the refusal of marketing authorization applications submitted for the product under the Tuznue and Hervelous labels.

While Prestige did not immediately respond to Generics Bulletin enquiries over the next steps for the application, the CHMP noted...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.